Cargando…

Case report: short time reversible myocardial dysfunction in sepsis treated with drotrecogin alpha

Detalles Bibliográficos
Autores principales:	Costa-Filho, RC, Costa, FJL, Gomes, PN, Martins, JR, Rabishoffski, A, Garcez, MF, Garcia, MI, Mesquita, AM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3301022/ http://dx.doi.org/10.1186/cc2220

Ejemplares similares

Resolution of Staphylococcus aureus (methicillin-resistant Staphylococcus aureus) osteomyelitis by oral linezolid
por: Gomes, PN, et al.
Publicado: (2003)

Cost effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis in hospitalised patients
por: Launois, R, et al.
Publicado: (2002)

Impact of renal scintigraphy in severe patients with acute renal failure
por: Ferreira, JF, et al.
Publicado: (2005)

The use of radionuclide-labeled white blood cell scintigraphy and (67)gallium scintigraphy in critically ill patients with sepsis
por: Corrêa, PL, et al.
Publicado: (2003)

Introduction: severe sepsis and drotrecogin alfa (activated)
por: Artigas, Antonio, et al.
Publicado: (2007)

Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
por: Costa, Vania, et al.
Publicado: (2007)

Clinical trials in severe sepsis with drotrecogin alfa (activated)
por: Laterre, Pierre-François
Publicado: (2007)

Timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Choi, Goda, et al.
Publicado: (2006)

The use of renal scintigraphy with technetium-99m-L,L-ethylenedicysteine in critically ill patients with acute renal failure in the intensive care unit
por: Corrêa, PL, et al.
Publicado: (2003)

Percutaneous multidilatational tracheostomy endoscopic guided: a simple and safe bedside procedure done by intensivists
por: Costa, RC, et al.
Publicado: (2001)

Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism?
por: Samama, Charles Marc, et al.
Publicado: (2011)

Gene array transcript profiling of human endothelial cells identifies pathways regulated by Drotrecogin alfa (activated)
por: Brueckmann, M, et al.
Publicado: (2003)

Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort
por: Hodder, Richard V, et al.
Publicado: (2009)

Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death
por: Friedrich, Jan O, et al.
Publicado: (2006)

Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
por: Levy, Howard, et al.
Publicado: (2005)

Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis
por: de Pont, Anne CJM, et al.
Publicado: (2009)

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis
por: Bernard, Gordon R, et al.
Publicado: (2003)

Severe sepsis and drotrecogin alfa (activated) use: results from the PROGRESS registry
por: Beale, R, et al.
Publicado: (2007)

Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis
por: Annane, Djillali, et al.
Publicado: (2018)

Tenecteplase for ST-elevation myocardial infarction in a patient treated with drotrecogin alfa (activated) for severe sepsis: a case report
por: Barra, Lillian, et al.
Publicado: (2009)

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death
por: Gupta, Sanjay, et al.
Publicado: (2006)

Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
por: Sadique, M Zia, et al.
Publicado: (2011)

Neuroaxial catheters following abdominal surgery and their impact on the use of Drotrecogin alfa (activated) in sepsis
por: Steel, A, et al.
Publicado: (2004)

The safety profile of drotrecogin alfa (activated)
por: Fumagalli, Roberto, et al.
Publicado: (2007)

Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
por: Friedrich, Jan O, et al.
Publicado: (2006)

Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock
por: Spapen, Herbert, et al.
Publicado: (2010)

The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes
por: Martin, Greg, et al.
Publicado: (2009)

Drotrecogin alfa in sepsis: analysis of outcomes in a UK district general intensive care unit
por: Pathak, H, et al.
Publicado: (2004)

Comparison of antimicrobial resistance rates in an ICU in Rio de Janeiro, Brazil and the United States
por: Santos, MS, et al.
Publicado: (2005)

Bilevel plus PSV and nitric oxide as an alternative ventilatory strategy in acute respiratory distress syndrome patients
por: Saddy, F, et al.
Publicado: (2007)

Treatment of Severe Sepsis: Where Next? Current and Future Treatment Approaches After the Introduction of Drotrecogin Alfa
por: Rice, Todd W
Publicado: (2006)

Drotrecogin alfa in patients with severe sepsis: experience from a tertiary care center in North India
por: Chawla, R, et al.
Publicado: (2007)

Testing of anti-activated protein C antibodies in four drotrecogin alfa (activated) severe sepsis studies
por: Yan, S, et al.
Publicado: (2008)

Practical aspects of treatment with drotrecogin alfa (activated)
por: Camporota, Luigi, et al.
Publicado: (2007)

Increasing microcirculation after drotrecogin alfa (activated)
por: Donati, A, et al.
Publicado: (2007)

Retrospective observational outcomes for drotrecogin alfa (activated)
por: Cameron, C, et al.
Publicado: (2007)

The client with chest pain in the emergency unit: educational strategy concerning early signals and symptoms in acute myocardial infarction
por: Andrade, KB, et al.
Publicado: (2001)

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis – practical aspects at the bedside and patient identification
por: Laterre, Pierre-François, et al.
Publicado: (2003)

Drotrecogin alfa (activated): current evidence supports treatment for severe sepsis patients with a high risk of death
por: Williams, Mark D, et al.
Publicado: (2006)

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Vincent, Jean-Louis, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_qcfj1ohh4oc04rl7h02s20g7ej